Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Oncol Lett
2018 Apr 01;154:4503-4510. doi: 10.3892/ol.2018.7859.
Show Gene links
Show Anatomy links
Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.
Ma Y
,
Chen K
,
Yang Z
,
Guan M
.
???displayArticle.abstract???
Lung cancer is the most common type of malignancy to metastasize to the brain, with the median survival time of patients being 6-11 months. In the present study, the aim was to compare the actionable gene mutation profiles of primary lung adenocarcinoma (LC) samples and LC brain metastasis (LCBM) samples through targeted sequencing. Next generation sequencing (NGS) of 13 formalin-fixed, paraffin-embedded LC samples and 15 LCBM samples was performed using a customized OncoAim™ cancer panel and OncoAim™ RNA fusion panel on the MiSeq platform. The OncoAim™ cancer panel pipeline and OncoAim™ RNA fusion panel pipeline were used for bioinformatic analysis. Together, 43 variants were observed in 7 genes from the 28 cancer samples. The mutated genes of LCBM were tumor protein (TP)53, epidermal growth factor receptor (EGFR), catenin β1, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α, mothers against decapentaplegic homolog 4, Kirsten rat sarcoma viral oncogene homolog (KRAS) and proto-oncogene B-Raf, which were exhibited in 10/15 (66.7%), 6/15 (40.0%), 3/15 (20.0%), 2/15 (13.3%), 2/15 (13.3%), 1/15 (6.7%) and 1/15 (6.7%) of samples, respectively. The mutated genes of LC were TP53, EGFR and KRAS, which were exhibited in 11/13 (84.6%), 5/13 (38.5%) and 2/13 (18.2%) of samples, respectively. echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase rearrangements were present in 1 LCBM sample. For 2 LC samples and 1 LCBM sample, no genetic alterations were observed. The NGS data also revealed a novel 4-codon deletion of TP53 (p.V166_H169del) and a novel TP53 splice site mutation (7577157-63del TACTCAG). Further potentially actionable mutations were detected in LCBM, indicating a high degree of genetic heterogeneity between the LC and LCBM samples that were analyzed. The present study demonstrated that NGS provides an improved approach for the discovery of potentially actionable mutations and the understanding of the mechanisms underlying tumor progression and evolution.
Andrews,
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
2004, Pubmed
Andrews,
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
2004,
Pubmed
Arrieta,
Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).
2015,
Pubmed
Bailon,
[Management of brain metastases from non-small cell lung carcinoma].
2011,
Pubmed
Boland,
Clinical next generation sequencing to identify actionable aberrations in a phase I program.
2015,
Pubmed
Cancer Genome Atlas Research Network,
Comprehensive molecular profiling of lung adenocarcinoma.
2014,
Pubmed
Cardarella,
The impact of genomic changes on treatment of lung cancer.
2013,
Pubmed
Detterbeck,
The Eighth Edition Lung Cancer Stage Classification.
2017,
Pubmed
Dienstmann,
Genomic medicine frontier in human solid tumors: prospects and challenges.
2013,
Pubmed
Ellis,
Whole-genome analysis informs breast cancer response to aromatase inhibition.
2012,
Pubmed
Frampton,
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
2013,
Pubmed
Gadgeel,
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
2014,
Pubmed
Gallione,
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).
2004,
Pubmed
Hagemann,
Clinical next-generation sequencing in patients with non-small cell lung cancer.
2015,
Pubmed
Han,
Mutation in the TP53 gene in colorectal carcinoma detected by polymerase chain reaction.
1991,
Pubmed
Imielinski,
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
2012,
Pubmed
Kitaeva,
Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors.
1997,
Pubmed
Lai,
Splicing mutations of the p53 gene in human hepatocellular carcinoma.
1993,
Pubmed
Lemjabbar-Alaoui,
Lung cancer: Biology and treatment options.
2015,
Pubmed
Lindeman,
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
2013,
Pubmed
Lindeman,
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
2013,
Pubmed
Mao,
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
2010,
Pubmed
Movva,
Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.
2015,
Pubmed
Mulvenna,
The management of brain metastases in patients with non-small cell lung cancer-is it time to go back to the drawing board?
2010,
Pubmed
Mäki-Nevala,
Hot spot mutations in Finnish non-small cell lung cancers.
2016,
Pubmed
Paik,
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.
2015,
Pubmed
Preusser,
Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.
2015,
Pubmed
Riely,
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
2008,
Pubmed
Robinson,
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
2014,
Pubmed
Russo,
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
2015,
Pubmed
Shaw,
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
2014,
Pubmed
Sie,
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
2014,
Pubmed
Tartarone,
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
2013,
Pubmed
Ting,
Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment.
2012,
Pubmed
Torre,
Global cancer statistics, 2012.
2015,
Pubmed
Welsh,
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
2013,
Pubmed
Yanagisawa,
Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers.
2000,
Pubmed
Yu,
TGF-β/Smad signaling through DOCK4 facilitates lung adenocarcinoma metastasis.
2015,
Pubmed
Zer,
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.
2014,
Pubmed
Zheng,
The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations.
2016,
Pubmed
